A Randomized, Single Blind, Placebo Controlled Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Oral Doses and Repeat Escalating Oral Doses of GSK2251052 in Healthy Adult Subjects

NCT01262885 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

84

Enrollment

INDUSTRY

Sponsor class

Conditions

Infections, Bacterial

Interventions

DRUG: GSK2251052
DRUG: Placebo

Sponsor

GlaxoSmithKline